id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-333227-849bm17h	Grewal, Ekjot	Angioedema, ACE inhibitor and COVID-19	2020-09-09		.txt	text/plain	2564	160	46	Here, we report a case of a 57-year-old man, unknowingly with COVID-19, who presented to the emergency department with tongue swelling, shortness of breath and difficulty in speaking following 4 months taking benazepril, an ACE inhibitor. 23 The presentation of this case report is similar to our own: nonpitting oedema of the lower face in the absence of pruritus, leucocytosis with relative lymphopenia, elevated inflammatory markers and resolution of symptoms within 48 hours, although the marked difference is the chronic use of ACE inhibitor, whereas our patient began his medication 4 months prior to admission. An impairment of cytokine degradation, evident by an increase in the level of C-reactive protein, has been implicated as being the primary mechanism of angioedema under the use of ACE inhibitor drugs, 28 which greatly resembles the dramatic release of proinflammatory cytokines caused Findings that shed new light on the possible pathogenesis of a disease or an adverse effect by SARS-CoV-2 infection.	./cache/cord-333227-849bm17h.txt	./txt/cord-333227-849bm17h.txt